Manila Times Business
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA aloneGraftAssure™ assay doubles reliability of positive results in screening cohortIn for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80% NASHVILLE, Tenn., June 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced an onl
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Kaldvík AS - Updated financial calendar
1h ago
Scott Alldridge Releases New Book Showing Why Most Cybersecurity Breaches Stem from Governance Failures Rather Than Technology Weaknesses
1h ago
Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
1h ago
NowVertical Appoints Andre Garber as Interim CEO of the Company
1h ago